Evidence map›Paper›PMID 40181162›Full record

ArticleGenes and immunity2025

Transcript-targeted antigen mapping reveals the potential of POSTN splicing junction epitopes in glioblastoma immunotherapy.

Zujian Xiong, Chaim T Sneiderman, Chloe R Kuminkoski, Jared Reinheimer, Lance Schwegman, ReidAnn E Sever, Ahmed Habib, Baoli Hu, Sameer Agnihotri, Dhivyaa Rajasundaram and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Genes and immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Zujian XiongDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Chaim T SneidermanDepartment of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
Chloe R KuminkoskiDepartment of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
Jared ReinheimerDepartment of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
Lance SchwegmanDepartment of Molecular Microbiology and Immunology, University of Texas at San Antonio, San Antonio, TX, USA.
ReidAnn E SeverDepartment of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
Ahmed HabibDepartment of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
Baoli HuDepartment of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
Sameer AgnihotriDepartment of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
Dhivyaa RajasundaramDepartment of Pediatrics, University of Pittsburgh, Pittsburgh, PA, USA.
Pascal O ZinnDepartment of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
Thomas G ForsthuberDepartment of Molecular Microbiology and Immunology, University of Texas at San Antonio, San Antonio, TX, USA.
Ian F PollackDepartment of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, USA.ORCID 0000-0003-1765-357X
Xuejun LiDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Itay RaphaelDepartment of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
Gary KohanbashDepartment of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, USA. gary.kohanbash2@chp.edu.ORCID 0000-0002-3953-8022

Funding

UTSA ESTEEMED ProgramR25EB027605 · NIBIB · UNIVERSITY OF TEXAS SAN ANTONIO · PI ABU-LAIL, NEHAL IBRAHIM · 2019 to 2024
$1.6M
MARC at the University of Texas at San AntonioT34GM145507 · NIGMS · UNIVERSITY OF TEXAS SAN ANTONIO · PI BAREA-RODRIGUEZ, EDWIN J, CASSILL, AARON · 2022 to 2024
$1.5M
NIBIB NIH HHS R25 EB027605NIGMS NIH HHS T34 GM145507
6 · The paper itself

Abstract

Tumor antigens are crucial for T-cell mediated immunotherapy, but identified antigens for gliomas remain limited. Aberrant splicing variants are commonly expressed in tumors, resulting in unique tumor isoforms with potential antigenic properties. Herein, we analyzed multi-omics data from 587 glioma patients and assembled a library of putative tumor-enriched isoform antigens (TIA) and corresponding peptides presented on each HLA-I allele. We constructed an individual-specific TIA peptide candidate repertoire for each patient based on their TIA expression and HLA-I haplotypes. TIAs were highly expressed, enriched with glioma malignancy, and demonstrated strong HLA-binding affinity. We focused on periostin isoform-203 (POSTN-203), which was associated with poor survival of patients and contained multiple predicted HLA-restricted peptide epitopes. A selected HLA-A11-restricted peptide from POSTN-203 (POSTN-203

Indexed as

Antigens, NeoplasmCell Adhesion MoleculesCentral Nervous System NeoplasmsEpitopesGlioblastomaHistocompatibility Antigens Class ITranscription, GeneticAgedAlternative SplicingHumansImmunologic TechniquesImmunotherapyMaleMiddle AgedProtein Interaction MappingProtein IsoformsAntigens, NeoplasmCell Adhesion MoleculesEpitopesHistocompatibility Antigens Class IPOSTN protein, humanProtein Isoforms

Identifiers

PMID40181162

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.